Valproic acid prevents NMDA-induced retinal degeneration in marmosets

IF 2.5 4区医学 Q3 NEUROSCIENCES

Neuroscience Letters Pub Date : 2025-03-14 DOI:10.1016/j.neulet.2025.138197

Takahiko Noro , Xiaoli Guo , Kazuhiko Namekata , Youichi Shinozaki , Nanako Hashimoto , Keiko Moriya-Ito , Chikako Harada , Tadashi Nakano , Takayuki Harada

{"title":"Valproic acid prevents NMDA-induced retinal degeneration in marmosets","authors":"Takahiko Noro , Xiaoli Guo , Kazuhiko Namekata , Youichi Shinozaki , Nanako Hashimoto , Keiko Moriya-Ito , Chikako Harada , Tadashi Nakano , Takayuki Harada","doi":"10.1016/j.neulet.2025.138197","DOIUrl":null,"url":null,"abstract":"<div><div>Valproic acid (VPA) is a prescribed drug widely used for treatment of epilepsy, mood disorders, migraines and neuropathic pain. Accumulating evidence suggests that VPA possess neuroprotective properties. Glaucoma, one of the leading causes of vision loss in the world, is characterized by progressive degeneration of retinal ganglion cells (RGCs) and their axons. Intravitreal injection of <em>N</em>-methyl-D-aspartate (NMDA) is well studied in rodents as an acute model of RGC death. In the present study, we first investigated whether NMDA induced retinal degeneration in non-human primate common marmosets as the structure and function of the eye is similar to that of humans. We found that NMDA had no effects on intraocular pressure but induced retinal degeneration by using optical coherence tomography and multifocal electroretinogram, both of which are non-invasive methods. In addition, VPA treatment suppressed acute retinal degeneration and ameliorated visual impairment in marmosets. Our findings raise intriguing possibilities that VPA may be useful for preventing RGC death and suggest that the marmoset is a useful animal model for studying glaucoma.</div></div>","PeriodicalId":19290,"journal":{"name":"Neuroscience Letters","volume":"855 ","pages":"Article 138197"},"PeriodicalIF":2.5000,"publicationDate":"2025-03-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Neuroscience Letters","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0304394025000850","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"NEUROSCIENCES","Score":null,"Total":0}

引用次数: 0

Abstract

Valproic acid (VPA) is a prescribed drug widely used for treatment of epilepsy, mood disorders, migraines and neuropathic pain. Accumulating evidence suggests that VPA possess neuroprotective properties. Glaucoma, one of the leading causes of vision loss in the world, is characterized by progressive degeneration of retinal ganglion cells (RGCs) and their axons. Intravitreal injection of N-methyl-D-aspartate (NMDA) is well studied in rodents as an acute model of RGC death. In the present study, we first investigated whether NMDA induced retinal degeneration in non-human primate common marmosets as the structure and function of the eye is similar to that of humans. We found that NMDA had no effects on intraocular pressure but induced retinal degeneration by using optical coherence tomography and multifocal electroretinogram, both of which are non-invasive methods. In addition, VPA treatment suppressed acute retinal degeneration and ameliorated visual impairment in marmosets. Our findings raise intriguing possibilities that VPA may be useful for preventing RGC death and suggest that the marmoset is a useful animal model for studying glaucoma.

查看原文本刊更多论文

求助全文

约1分钟内获得全文求助全文

来源期刊

Neuroscience Letters 医学-神经科学

CiteScore

5.20

自引率

0.00%

发文量

408

审稿时长

50 days

期刊介绍： Neuroscience Letters is devoted to the rapid publication of short, high-quality papers of interest to the broad community of neuroscientists. Only papers which will make a significant addition to the literature in the field will be published. Papers in all areas of neuroscience - molecular, cellular, developmental, systems, behavioral and cognitive, as well as computational - will be considered for publication. Submission of laboratory investigations that shed light on disease mechanisms is encouraged. Special Issues, edited by Guest Editors to cover new and rapidly-moving areas, will include invited mini-reviews. Occasional mini-reviews in especially timely areas will be considered for publication, without invitation, outside of Special Issues; these un-solicited mini-reviews can be submitted without invitation but must be of very high quality. Clinical studies will also be published if they provide new information about organization or actions of the nervous system, or provide new insights into the neurobiology of disease. NSL does not publish case reports.